Application of mechanism-based CYP inhibition for predicting drug-drug interactions (Q37494640)

20 August 2017

1 reference

title

Application of mechanism-based CYP inhibition for predicting drug-drug interactions (English)

1 reference

20 August 2017

0 references

1 reference

Zhi-Wei Zhou

1

1 reference

PubMed ID

19466877

20 August 2017

Shu-Feng Zhou

series ordinal

2

1 reference

PubMed ID

19466877

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

6

1 reference

20 August 2017

579-605

1 reference

Drug-drug interactions of new active substances: mibefradil example

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Screening for human ADME/Tox drug properties in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Clinical importance of the cytochromes P450

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Clinical pharmacogenetics and potential application in personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Methods for predicting in vivo pharmacokinetics using data from in vitro assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Time-dependent CYP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Possible inhibition of hepatic metabolism of quinidine by erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Drug interactions with cisapride: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Cardiovascular drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Elucidating mechanisms of drug-induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Selective protein covalent binding and target organ toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Transient-phase kinetics of enzyme inactivation induced by suicide substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Structural and mechanistic insight into the inhibition of aspartic proteases by a slow-tight binding inhibitor from an extremophilic Bacillus sp.: correlation of the kinetic parameters with the inhibitor induced conformational changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Predicting in vivo drug interactions from in vitro drug discovery data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Kinetics of suicide substrates. Practical procedures for determining parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Commentary: a physiological approach to hepatic drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

21 January 2018

Drug metabolite kinetics

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Dose of midazolam should be reduced during diltiazem and verapamil treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subje

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Inhibition of alfentanil metabolism by erythromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902926099

10.1517/17425250902926099

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19466877